Viridian Capital & Research Release Cannabis Industry Update: Legal Cannabis Sector Gets Boost from 2014 Midterm

posted in: Hemp Legislation 0


New York, NY (PRWEB) November 05, 2014

The legalization of recreational marijuana in Alaska, Oregon and the District of Columbia will propel the cannabis sector in several key ways, from increasing the flow of capital into legal marijuana companies to setting up a 2016 legalization push in California, Viridian Capital & Research believes.

Even the losing vote for medical marijuana in Florida supports the secular growth of this market, Viridian believes, since the measure nearly passed despite mistakes by its backers, who unnecessarily associated the measure with partisan Democratic politics during a Republican landslide election.

Oregon and Alaska now join Colorado and Washington State, which legalized recreational marijuana in 2012. State officials in Oregon and Alaska will move to create the administrative system for marijuana sales, which are expected to begin in both states by 2016. Voters in the District of Columbia passed what has been called “soft legalization,” which allows citizens to possess and grow small amounts of marijuana, but does not create cannabis stores (the DC initiative must also be approved by Congress, where opposition is already brewing.)

The successful legislation in Oregon, Alaska, and the District of Columbia, along with the close result in Florida, will make 2015 a critical year for the cannabis industry. These midterm results will offer law makers in other states the confidence to introduce new initiatives for action in 2015 and placement on 2016 ballots. This trend will be accelerated if the sale of recreational marijuana in Colorado and Washington State appears to be a success, which appears likely.

Conclusion

Viridian expects the following actions resulting from yesterday’s elections:


    More Bills to Legalize Recreation Cannabis: Viridian believes several states will see bills in 2015 to legalize recreational marijuana and that legalization could be on the ballot in 7-13 states –most notably California — during the 2016 elections.

    Emergence of Marijuana as a 2016 Presidential Election Issue: Viridian’s sources suggest that both Republican and Democratic parties may adopt pro legal-cannabis positions and talking points during the 2016 Presidential elections.

    Marijuana Tax Battles, Starting with Oregon and Washington State: Oregon’s imposed tax of $ 35 per ounces, is less than Colorado and more importantly less its neighbor to the north, Washington State. Due to high taxes in Washington, consumers can expect an ounce of cannabis in Seattle to cost over $ 500. Compared to it costing consumers anywhere from $ 145 – $ 200 an ounce when Oregon goes live. As a result, Viridian believes that this could negatively impact the Washington market, since many consumers will just travel across the border to purchase recreational cannabis at a much lower cost.

    Continued Increase in Cannabis Sales, Profits and Tax Revenues: The continued efforts of states beginning to roll out their respective legal cannabis markets will result in additional states having recreational cannabis markets online, an increased number of total licenses in the US being granted to qualified entrepreneurs, and numerous dispensaries opening up in these markets. Viridian believes these factors support its estimate of the cannabis industry growing to over $ 10 billion dollars by 2018.

    Growth of the Capital Markets for Cannabis Companies: Viridian expects continued growth in the number of cannabis companies looking to access the capital markets to raise growth capital and/or execute M&A strategies. As valuations in the public cannabis companies continue to rationalize, we may see increasing interest on the part of investment funds to take equity stakes in cannabis enterprises, versus the straight debt and convertible debt financing that has made up the bulk of financing in public cannabis companies to date.

    Movement in Public Cannabis Market Stock Index: Viridian expects continued volatility in the public markets for the cannabis industry, which have seen lofty valuations, rampant speculation, and increased regulatory oversight. The “whipsaw” nature of these companies’ stock price and volume has created a “Wild West” environment that attracts retail traders, momentum investors and shorts. Volatility was especially pronounced leading up to the 2012 elections, when Colorado and Washington voted to legalize recreational marijuana, as well as the months following. This continued around the launch of Colorado’s recreational cannabis market in January 2014. Following these events, the cannabis sector experienced significant contractions after momentum from the hype and promotion died down and valuations began to rationalize. For more on the cannabis stocks sector see the charts below and the Viridian Cannabis Stock Index report at: http://viridiancr.com/industry-report

Snapshots of Measures Voted on Yesterday:

Oregon

Oregon passed the “Control, Regulation, and Taxation of Marijuana and Industrial Hemp Act,” which will implement a system similar to that in Washington State, but with lower taxes. The measure allows residents 21 and older to possess up to eight ounces of marijuana — a considerable increase from the single ounce permitted by Colorado and Washington. It grants the Oregon Liquor Control Commission primary oversight and regulatory authority over the sector, with input from the state’s Department of Agriculture and the Oregon Health Authority. Four types of cannabis businesses will be permitted: Cannabis producers, who cultivate marijuana for wholesale; cannabis processors, who produce cannabis extracts and products; cannabis wholesalers, who purchase cannabis and cannabis products to sell to retailers and other non-consumers; and cannabis retailers, who sell cannabis and cannabis products to individuals 21 and older. One of the most important features of the act is its level of state tax on marijuana, assessed by weight. Oregon’s tax of $ 35 per ounces is less than Colorado and more importantly, far lower than its neighbor to the north, Washington State. Due to high taxes in Washington, consumers can expect an ounce of cannabis in Seattle to cost over $ 500. In contrast, in Oregon recreational cannabis will cost anywhere from $ 145 – $ 200 an ounce. Many believe this will hit Washington cannabis companies hard, as users need only jump across the border to get a dramatic discount on their marijuana.

Alaska

Alaska’s successful Ballot Measure 2 has many similarities to Oregon’s Measure 91. An important difference is that Alaska’s law allows the state legislature to create a new Marijuana Control Board – failing that, Alaska’s Alcohol Beverage Control Board will be tasked with creating regulations and licensing requirements. There will be much work to do, since the state has limited administrative frameworks around its medical marijuana system. For example, the Alaska lacks a regulated wholesale system, but rather relies on “home grows” and caregivers for production and supply of cannabis to the medical market. As a result, Alaska will need to work with experts from other recreational and medical cannabis states to design and implement regulations for the recreational market.

Washington, D.C.

Voters in the District of Columbia passed Initiative 71 Tuesday night. Earlier this year D.C. implemented a marijuana decriminalization bill, which removed all criminal penalties for possession of up to an ounce of cannabis and replaced them with a civil fine of $ 25. Initiative 71 takes decriminalization a step further, allowing adults 21 years and older to possess up to two ounces of marijuana and cultivate up to six plants (with no more than three being mature) in their private residences. Adults could give away up to an ounce of marijuana, but sales would still be criminal. The initiative also removes penalties for use and sale of marijuana paraphernalia. However, Congress has to approve the new law. That risk, plus the lack of a commercial framework in the current measure and the District’s existing medical marijuana system, indicate recreational marijuana sales are not likely to reach DC in the near future.

Florida

Florida’s medical marijuana amendment earned a majority of the votes but failed to reach the 60% needed to pass. Many observers attribute the failure to errors by the measure’s key backers, which gave the measure a democratic partisan hue on a Republican day, plus the generally older and more conservative makeup of the midterm electorate.

Supporters pledge to take the fight to the 2015 Florida legislative session and, if that fails, have it back on the ballot in 2016. Given how close the measure came to passing this year, it appears likely medical marijuana is in the future of Floridians.

Viridian Capital & Research

Viridian Capital & Research (VCR) http://www.viridiancr.com @ViridianCap was formed by experienced investment bankers to bring capital markets expertise, institutional research coverage and strategic direction to the emerging Cannabis Sector. VCR is a boutique banking and strategic advisory firm that helps clients improve the value of their enterprises by providing research, investment banking, investor relations and corporate development services. Our banking practice, through affiliate Pickwick Capital Partners, provides capital and M&A services to fund the growth of our clients, while our advisory practice helps position and build their cannabis businesses. VCR research and market intelligence are recognized for their unique value and cited by leading market observers, including Institutional Investor.

Broker dealer services provided through Pickwick Capital Partners, LLC Member FINRA SIPC.







Related Hemp Legislation Press Releases

Dairy Alternative Beverages Market to Grow at 15.74% CAGR by 2018 Forecasts a New Research Report at Sandlerresearch.org

posted in: Hemp Farming 0

Dallas, Texas (PRWEB) July 15, 2014

Many people are adopting a vegan diet as a result of their ethical concerns about animal rights, protecting the environment, and saving the planet. Nowadays, veganism has become a lifestyle choice and a more widely known philosophy. The vegan diet does not include anything of animal origin. According to PETA, about 2.5 percent of the US population is vegan. In addition, people perceive a vegan diet to be healthy and prefer consuming dairy alternatives such as soy milk, almond milk, rice milk, coconut milk, hazelnut milk, oat milk, and hemp milk as a substitute for dairy milk. Analysts forecast the Global Dairy Alternative Beverages market will grow at a CAGR of 15.74 percent over the period 2013-2018. According to the report, several factors drive the growth of the Global Dairy Alternative Beverages market. The increased health benefit is one of the major drivers in the market.

The Global Dairy Alternative Beverages market can be segmented into four divisions: Soya Milk, Almond Milk, Rice Milk, and Others. These are the major substitutes for milk, which are widely consumed by the consumers worldwide.

Global Dairy Alternative Beverages Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Dairy Alternative Beverages market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The report recognizes the following companies as the key players in the Global Dairy Alternative Beverages Market: Organic Valley Family of Farms, Sanitarium Health & Wellbeing Co., The Hain Celestial Group Inc., The WhiteWave Foods Co., Blue Diamond Growers Inc., Earth’s Own FoodCompanyInc., Eden Foods Inc., Freedom Foods Group Ltd, Living Harvest Foods Inc., Nutriops S.L., OATLY AB, Pacific Natural Foods, Panos Brands LLC, Pureharvest Foods, Stremicks Heritage Foods, SunOpta Inc., Turtle Mountain LLC, Vitasoy International Holdings Ltd.

Purchase report at http://www.sandlerresearch.org/purchase?rname=19359.

Key Regions

    Americas
    APAC
    Europe
    ROW

Key Market Driver

    Increasing Demand for the Dairy Alternative Beverages due to its Health Benefits.

Key Market Challenge

    Threat of Cross-contamination.

Key Market Trend

    Rising Concern for the Vegan Diet.

Further, the report states that despite the presence of several drivers, the growth of the market is curtailed by certain challenges. The threat of cross-contamination of raw materials is a major challenge that limits the growth of the market.

Key Questions Answered in this Report

    What will the market size be in 2018 and what will the growth rate be?
    What are the key market trends?
    What is driving this market?
    What are the challenges to market growth?
    Who are the key vendors in this market space?
    What are the market opportunities and threats faced by the key vendors?
    What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Product

07.1 Global Dairy Alternative Beverages Market by Product Types 2013

07.1.1 Overview of the Global Health and Wellness Market by Product Type 2013-2018

08. Geographical Segmentation

08.1 Global Dairy Alternative Beverages Market by Geographical Segmentation 2013-2018

08.2 Overview of Global Dairy Alternative Beverages Market by Geography

08.3 Dairy Alternative Beverages Market in the APAC Region

08.3.1 Market Size and Forecast

08.4 Dairy Alternative Beverages in the Americas

08.4.1 Market Size and Forecast

08.5 Dairy Alternative Beverages Market in Europe

08.5.1 Market Size and Forecast

08.6 Dairy Alternative Beverages Market in the ROW

08.6.1 Market Size and Forecast

09. Key Leading Countries

09.1 China

09.2 USA

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

17.1 Competitive Scenario

17.1.1 Key News

17.1.2 Mergers and Acquisitions

17.2 Market Analysis 2013

17.3 Other Prominent Vendors

18. Key Vendor Analysis

19. Other Reports in this Series

18 – List of Exhibits

Browse other new reports on Food and Beverage Market, Hot Drinks Market.

About US:

Sandlerresearch.org (http://www.sandlerresearch.org/) is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.







Related Hemp Farming Press Releases

Scientific Research and Real Facts about the Cannabinoids in Cannabis

posted in: Cannabis Science 17

PLEASE WATCH AND SHARE THIS VIDEO
NEW Documentary – http://youtu.be/XfO_MpDm5kc
Legalize Cannabis – http://petition.liberal.ca/end-prohibition

Cannabinoid Research

ncbi.nlm.nih.gov/pmc/articles/PMC3442177

ncbi.nlm.nih.gov/pmc/articles/PMC2828614

ncbi.nlm.nih.gov/pmc/articles/PMC2604798

ncbi.nlm.nih.gov/pmc/articles/PMC2872061

ncbi.nlm.nih.gov/pmc/articles/PMC2225529

ncbi.nlm.nih.gov/pmc/articles/PMC2812803

ncbi.nlm.nih.gov/pmc/articles/PMC2277494

ncbi.nlm.nih.gov/pmc/articles/PMC2823358

ncbi.nlm.nih.gov/pmc/articles/PMC2898685

ncbi.nlm.nih.gov/pmc/articles/PMC2925907

ncbi.nlm.nih.gov/pmc/articles/PMC2819831

ncbi.nlm.nih.gov/pmc/articles/PMC2936031

ncbi.nlm.nih.gov/pmc/articles/PMC2866040

ncbi.nlm.nih.gov/pmc/articles/PMC2829220

ncbi.nlm.nih.gov/pmc/articles/PMC3023979

ncbi.nlm.nih.gov/pmc/articles/PMC2936031

ncbi.nlm.nih.gov/pmc/articles/PMC3034694

ncbi.nlm.nih.gov/pmc/articles/PMC3230631

ncbi.nlm.nih.gov/pmc/articles/PMC3232190

ncbi.nlm.nih.gov/pmc/articles/PMC3165947

ncbi.nlm.nih.gov/pmc/articles/PMC3096803

ncbi.nlm.nih.gov/pmc/articles/PMC2071638

ncbi.nlm.nih.gov/pmc/articles/PMC1892413

ncbi.nlm.nih.gov/pmc/articles/PMC2270485

ncbi.nlm.nih.gov/pmc/articles/PMC1592672

ncbi.nlm.nih.gov/pmc/articles/PMC2430692

ncbi.nlm.nih.gov/pmc/articles/PMC2189767

ncbi.nlm.nih.gov/pmc/articles/PMC2664885

ncbi.nlm.nih.gov/pmc/articles/PMC2765124

ncbi.nlm.nih.gov/pmc/articles/PMC2737440

ncbi.nlm.nih.gov/pmc/articles/PMC2955420

ncbi.nlm.nih.gov/pmc/articles/PMC2682269

ncbi.nlm.nih.gov/pmc/articles/PMC2451037

ncbi.nlm.nih.gov/pmc/articles/PMC2592995

ncbi.nlm.nih.gov/pmc/articles/PMC3316151

ncbi.nlm.nih.gov/pubmed/19638490

ncbi.nlm.nih.gov/pubmed/22776349

ncbi.nlm.nih.gov/pubmed/16682966

ncbi.nlm.nih.gov/pubmed/12648025

ncbi.nlm.nih.gov/pubmed/19914218

ncbi.nlm.nih.gov/pubmed/16893424

ncbi.nlm.nih.gov/pubmed/15361550

ncbi.nlm.nih.gov/pubmed/19889794

ncbi.nlm.nih.gov/pubmed/19015962

ncbi.nlm.nih.gov/pubmed/19608284

ncbi.nlm.nih.gov/pubmed/17237277

ncbi.nlm.nih.gov/pubmed/11586361

ncbi.nlm.nih.gov/pubmed/14692532

ncbi.nlm.nih.gov/pubmed/16571653

ncbi.nlm.nih.gov/pubmed/18286801

ncbi.nlm.nih.gov/pubmed/16250836

ncbi.nlm.nih.gov/pubmed/17934890

ncbi.nlm.nih.gov/pubmed/12052046

ncbi.nlm.nih.gov/pubmed/19189054

ncbi.nlm.nih.gov/pubmed/18354058

ncbi.nlm.nih.gov/pubmed/19047095

ncbi.nlm.nih.gov/pubmed/10913156

ncbi.nlm.nih.gov/pubmed/9653194

ncbi.nlm.nih.gov/pubmed/18088200

ncbi.nlm.nih.gov/pubmed/16909207

ncbi.nlm.nih.gov/pubmed/17342320

ncbi.nlm.nih.gov/pubmed/19059457

ncbi.nlm.nih.gov/pubmed/12723496

ncbi.nlm.nih.gov/pubmed/19442536

ncbi.nlm.nih.gov/pubmed/16728591

ncbi.nlm.nih.gov/pubmed/19539619

ncbi.nlm.nih.gov/pubmed/16500647

ncbi.nlm.nih.gov/pubmed/19189659

ncbi.nlm.nih.gov/pubmed/14617682

ncbi.nlm.nih.gov/pubmed/18938775

ncbi.nlm.nih.gov/pubmed/11106791

ncbi.nlm.nih.gov/pubmed/19394652

ncbi.nlm.nih.gov/pubmed/20336665

ncbi.nlm.nih.gov/pubmed/19442435

ncbi.nlm.nih.gov/pubmed/15451022

ncbi.nlm.nih.gov/pubmed/18197164

ncbi.nlm.nih.gov/pubmed/16835997

ncbi.nlm.nih.gov/pubmed/11903061

ncbi.nlm.nih.gov/pubmed/17675107

ncbi.nlm.nih.gov/pubmed/17202146

ncbi.nlm.nih.gov/pubmed/19425170

ncbi.nlm.nih.gov/pubmed/18454173

ncbi.nlm.nih.gov/pubmed/17065222

ncbi.nlm.nih.gov/pubmed/10700234

ncbi.nlm.nih.gov/pubmed/16787257

ncbi.nlm.nih.gov/pubmed/15958274

ncbi.nlm.nih.gov/pubmed/16139274

ncbi.nlm.nih.gov/pubmed/16624285

ncbi.nlm.nih.gov/pubmed/16616335

ncbi.nlm.nih.gov/pubmed/11269508

ncbi.nlm.nih.gov/pubmed/19690545

ncbi.nlm.nih.gov/pubmed/12511587

ncbi.nlm.nih.gov/pubmed/20307616

ncbi.nlm.nih.gov/pubmed/16818634

ncbi.nlm.nih.gov/pubmed/17952650

ncbi.nlm.nih.gov/pubmed/16818650

ncbi.nlm.nih.gov/pubmed/16596790

ncbi.nlm.nih.gov/pubmed/15638794

ncbi.nlm.nih.gov/pubmed/15275820

ncbi.nlm.nih.gov/pubmed/12133838

ncbi.nlm.nih.gov/pubmed/18339876

ncbi.nlm.nih.gov/pubmed/9771884

ncbi.nlm.nih.gov/pubmed/10570948

ncbi.nlm.nih.gov/pubmed/12182964

ncbi.nlm.nih.gov/pubmed/19229996

ncbi.nlm.nih.gov/pubmed/20546877

ncbi.nlm.nih.gov/pubmed/19916793

ncbi.nlm.nih.gov/pubmed/21464819

ncbi.nlm.nih.gov/pubmed/9392925

ncbi.nlm.nih.gov/pubmed/19394652

ncbi.nlm.nih.gov/pubmed/20336665

ncbi.nlm.nih.gov/pubmed/21312237

ncbi.nlm.nih.gov/pubmed/23318578

ncbi.nlm.nih.gov/pubmed/21807457

ncbi.nlm.nih.gov/pubmed/21298280

ncbi.nlm.nih.gov/pubmed/22447182

ncbi.nlm.nih.gov/pubmed/23361273

ncbi.nlm.nih.gov/pubmed/16500647

google.com/patents/US4837228

google.com/patents/US4189491

google.com/patents/US5631297

google.com/patents/US6132762

google.com/patents/US6410588

google.com/patents/US6630507

google.com/patents/US7741365

google.com/patents/US7597910

google.com/patents/US8071641

google.com/patents/US8242178

google.com/patents/US8034843

cmcr.ucsd.edu

phoenixtears.ca

thesethgroup.org

herb.com/guzman.pdf

cannabis-med.org/index.php?lng=en

gwpharm.com/cannabinoids-science.aspx

phoenixtearsfoundation.com/scientific-studies
Video Rating: 4 / 5

4/20 Marijuana Documentary – Cannabis Research Studies – 2014

PLEASE WATCH AND SHARE THIS VIDEO
No Copyright – http://youtu.be/sYA9EpVB2qo
The Credits and Sources are found at 1:07:25
Legalize – http://petition.liberal.ca/end-prohibition

Cannabinoid Research

 

 

Click here to watch Episode 2 now: http://bit.ly/1phzPUb

In this episode of Canadian Cannabis, Damian visits two gigantic weed factories in Ontario to check out what kind of bud the government has legally authorized. He also chats with pot activists throughout British Columbia to get their take on the new licensed producer system. And, lastly, we visited a private pot grower who has a medical grow license, but is being squeezed out by Canada’s new medical marijuana program: the MMPR.

Click to watch Weediquette: STONED MOMS – http://www.vice.com/weediquette-show/stoned-moms-571

Check out the 4/20 playlist here: http://bit.ly/WbmMHD

Check out our full video catalog: http://bit.ly/VICE-Videos
Videos, daily editorial and more: http://vice.com
Like VICE on Facebook: http://fb.com/vice
Follow VICE on Twitter: http://twitter.com/vice
Read our tumblr: http://vicemag.tumblr.com
Follow us on instagram: http://instagram.com/vice

1 2